Last Updated: 04/06/07
A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase
http://www.cancer.gov/clinicaltrials/SWOG-S0325
Contacts:
Brian Jay Druker, M.D., study coordinator
503-494-5596
Marilyn Slovak, Ph.D., study coordinator
626-256-4673, ext. 62438; 800-826-4673
Peter Emanuel, M.D., study coordinator
205-934-6195, peter.emanuel@ccc.uab.edu
This trial, a Southwest Oncology Group study financed by CTEP and known as S0325, will assess the activity of dasatinib, a promising new oral targeted therapy in the front line treatment of chronic myelogenous leukemia (CML). Dasatinib has been shown to be effective in CML patients who are resistant or refractory to imatinib. The study is designed with three arms include ing imatinib treatment at standard and increased doses. Results of the trial may influence the standard of care for CML patients and will provide insights into trial designs for future CML studies that may include combinations of dasatinib and imatinib.
